Wednesday, December 11, 2019
Breaking Medical Device Industry News
Home TransEnterix Inc.

TransEnterix Inc.

    Broad Reimbursement Approval in Japan for Senhance Digital Laparoscopy System

    The reimbursement, which became effective on July 31, 2019, applies to 98 benign and malignant laparoscopic procedures across general, colorectal, gynecologic, bariatric and urologic surgeries at reimbursement rates equivalent to traditional laparoscopy in Category A1. The Senhance received regulatory approval from the Japanese MHLW on May 22, 2019.

    TransEnterix Receives FDA 510(k) Clearance for 3mm Diameter Instruments

    10/11/18: The clearance of the 3 millimeter diameter instruments will allow the Senhance to be used for microlaparoscopic surgeries, enabling surgeons to operate through tiny incisions considered virtually scarless for patients.

    TransEnterix Receives CE Mark Approval for Senhance Ultrasonic Instrument System

    10/1/18: “Advanced energy devices are an important tool for laparoscopic surgeons because of their applicability within a wide range of procedures,” said Todd M. Pope, TransEnterix CEO. “We believe the addition of the Senhance Ultrasonic will help drive broader penetration of Senhance and help advance digital laparoscopy in Europe and other countries that accept CE Mark around the world.”

    TransEnterix Announces FDA 510(k) Submission for 3mm Senhance Instruments

    6/8/18: “TransEnterix is the first company to seek FDA clearance for robotically-driven 3 millimeter instruments for abdominal surgery in the U.S.,” said Todd M. Pope, TransEnterix CEO. “We believe Senhance robotic assistance can enable surgeons to expand their use of virtually scarless surgery in more patients, and expands the value that robotics can bring over traditional manual approaches."

    TransEnterix Announces FDA 510(k) Submission for Senhance Indication Expansion to More than Double Addressable Market in the U.S. and Provides Commercial Update

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the Company has filed a FDA 510(k) submission to expand the indication for use of its Senhance™ Surgical System, and provided an update about commercial results thus far for the quarter ending March 31, 2018.

    TransEnterix Announces Senhance US Sale Agreement With Florida Hospital

    11/13/17: TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that Florida Hospital entered into an agreement to purchase the Company’s Senhance™ Surgical Robotic System.

    TransEnterix Annouced Enhanced Capability to Perform Micro Innces cision Robotic Surgery

    TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that...

    TransEnterix Announces Pricing of $24.9 Million Public Offering of Common Stock and Warrants

    TransEnterix, Inc. (NYSE MKT:TRXC) (“TransEnterix”), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, announced the pricing...

    TransEnterix Announces the Senhance™ Expansion into Robotic Hernia Repair

    TransEnterix, Inc. (NYSE MKT: TRXC) (“TransEnterix”), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced...

    RECENT COMMENTS